FIELD: medicine.
SUBSTANCE: group of inventions relates to medicine, namely to dermatology, and can be used to treat psoriasis. To do this, an adult patient who is a candidate for systemic therapy is injected subcutaneously with secoquinumab at 0, 1, 2, 3, 4, with a subsequent monthly administration.
EFFECT: it provides effective treatment of psoriasis, including at the onset of relapse.
17 cl, 11 dwg, 6 ex, 11 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS OF TREATING PSORIASIS USING IL-17 ANTAGONISTS | 2011 |
|
RU2591083C2 |
| USE OF IL-17 ANTAGONISTS FOR INHIBITION OF STRUCTURAL DAMAGE PROGRESSION IN PATIENTS WITH PSORIATIC ARTHRITIS | 2015 |
|
RU2697383C2 |
| METHODS OF TREATING RHEUMATOID ARTHRITIS USING IL-17 ANTAGONISTS | 2011 |
|
RU2582937C2 |
| METHODS OF TREATING NON-RADIOGRAPHIC AXIAL SPONDYLARTHRITIS BY USING INTERLEUKIN-17 (IL-17) ANTAGONISTS | 2016 |
|
RU2728710C2 |
| METHODS FOR TREATMENT USING ANTI-IL-17A ANTIBODIES | 2016 |
|
RU2754683C2 |
| METHODS OF TREATING PSORIASIS | 2008 |
|
RU2475265C2 |
| METHOD OF TREATING PSORIASIS (VERSIONS) | 2009 |
|
RU2497545C2 |
| AQUEOUS PHARMACEUTICAL COMPOSITION OF ANTI-IL17A ANTIBODY AND ITS APPLICATION | 2019 |
|
RU2754760C2 |
| METHOD OF TREATING AUTOIMMUNE DISEASE (VERSIONS) | 2009 |
|
RU2539110C2 |
| NEW INDICATIONS FOR USE IN TREATING ANTIBODIES AGAINST IL-1-BETA | 2014 |
|
RU2698208C2 |
